Seviteronel

Seviteronel
Clinical data
Other namesVT-464; INO-464
Routes of
administration		By mouth
Drug classAndrogen biosynthesis inhibitor; Nonsteroidal antiandrogen
ATC code
  • None
Identifiers
  • (1S)-1-[6,7-Bis(difluoromethoxy)naphthalen-2-yl]-2-methyl-1-(2H-triazol-4-yl)propan-1-ol
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H17F4N3O3
Molar mass399.346 g·mol−1
3D model (JSmol)
  • CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC(F)F)OC(F)F)(C3=NNN=C3)O
  • InChI=1S/C18H17F4N3O3/c1-9(2)18(26,15-8-23-25-24-15)12-4-3-10-6-13(27-16(19)20)14(28-17(21)22)7-11(10)5-12/h3-9,16-17,26H,1-2H3,(H,23,24,25)/t18-/m0/s1
  • Key:ZBRAJOQFSNYJMF-SFHVURJKSA-N

Seviteronel (developmental codes VT-464 and, formerly, INO-464) is an experimental cancer medication which is under development by Viamet Pharmaceuticals and Innocrin Pharmaceuticals for the treatment of prostate cancer and breast cancer.[1] It is a nonsteroidal CYP17A1 inhibitor and works by inhibiting the production of androgens and estrogens in the body.[1] As of July 2017, seviteronel is in phase II clinical trials for both prostate cancer and breast cancer.[1] In January 2016, it was designated fast-track status by the United States Food and Drug Administration for prostate cancer.[1][2] In April 2017, seviteronel received fast-track designation for breast cancer as well.[1]

  1. ^ a b c d e "Seviteronel - Innocrin Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG. Archived from the original on 2015-07-22. Retrieved 2015-07-20.
  2. ^ "FDA grants fast-track status for Innocrin's seviteronel to treat metastatic CRPC". PharmaceuticalTechnology. 6 January 2016. Archived from the original on 3 June 2016. Retrieved 2 May 2016.